Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03781362 · ClinicalTrials.gov registry record · Phase 1
Study of CPI-100 in Patients With Advanced Tumors
A Phase 1 study, sponsored by Coordination Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT03781362 is a Phase 1 study that has completed, run by Coordination Pharmaceuticals. The registered enrollment target is 36 participants.
The verdict
NCT03781362, a Phase 1 study, has completed, sponsored by Coordination Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
This is a prospective, open-label, 2-arm, non-randomized study of CPI-100 in patients with advanced tumors. CPI-100 is administered via intravenous infusion in a 3 + 3 study design to identify the maximum tolerated dose (MTD).
Interventions
- DRUG Capecitabine
- DRUG CPI-100
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2018-12-21 |
| Est. Completion | 2022-06-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03781362
The ClinicalTrials.gov registry entry for NCT03781362 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Coordination Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Capecitabine is the first listed.
NCT03781362 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03781362 about?
NCT03781362 is a clinical study titled "Study of CPI-100 in Patients With Advanced Tumors". This is a prospective, open-label, 2-arm, non-randomized study of CPI-100 in patients with advanced tumors. CPI-100 is administered via intravenous infusion in a 3 + 3 study design to identify the maximum tolerated dose (MTD).
What is the current status of trial NCT03781362?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2018-12-21. Estimated completion is 2022-06-21.
What interventions are being tested in trial NCT03781362?
The interventions under investigation include: Capecitabine (DRUG), CPI-100 (DRUG).
Who is sponsoring clinical trial NCT03781362?
This trial is sponsored by Coordination Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.